US · Healthcare · Diagnostics & Research
EPS came in at -0.10 against a street estimate of -0.13 — a beat of 23.1%.
Analysts rate Adaptive Biotechnologies Corp a buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $25.07.
CONFIDENT MRD revenue +49% ex-milestones on 43% clinical volume growth. Raised FY26 guidance to $268–$278M. Announced separation of Immune Medicine. Raised $340M convertible, retired debt. Tracking to positive EBITDA/FCF by year-end. Q2 2026 No regional breakdown provided. Analysts pressed on multiple myeloma saturation (pushback: only 17% penetrated), ASP path to $1,400 (reassured by payer actions), and serial testing upside (confirmed left out of guide). Management confident in heme runway and disciplined on M&A. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| Viking Global Investors LP | 4.70% |
| BlackRock Inc | 2.08% |
| Vanguard Capital Management, LLC | 0.95% |
| Wellington Management Company LLP | 0.93% |
| D. E. Shaw & Co LP | 0.72% |
| Vanguard Portfolio Management, LLC | 0.70% |
| Amvescap Plc. | 0.70% |
| Westfield Capital Management Company, L.P. | 0.67% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ADAPTIVE BIOTECHNOLOGIES CORPORATION – 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Revenue (6 months): $142.4 million, up 2 | 2026-08-04 |
| Results announced · Q3 2026 ADAPTIVE BIOTECHNOLOGIES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $71.6 million, up 22% year-over-year • MRD Revenue: $ | 2026-07-29 |
| Material agreement · Q2 2026 ADAPTIVE BIOTECHNOLOGIES CORPORATION – 8-K SUMMARY HEADLINE NUMBERS • $345 million in 0% Convertible Senior Notes issued on June 22, 2026, due July | 2026-06-22 |
| Company announcement · Q2 2026 ADAPTIVE BIOTECHNOLOGIES CORPORATION - 8-K SUMMARY HEADLINE NUMBERS • Company announced intention to offer $250 million in aggregate principal amoun | 2026-06-15 |
| Shareholder vote results · Q2 2026 ADAPTIVE BIOTECHNOLOGIES CORPORATION – 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 5, 2026 • Three proposals presented to sh | 2026-06-09 |
| Quarterly report · Q1 2026 ADAPTIVE BIOTECHNOLOGIES CORPORATION – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Quarterly Revenue: $70.9 million (Q1 2026) vs. $52.4 million (Q1 | 2026-05-05 |
| Proxy statement · Q2 2026 ADAPTIVE BIOTECHNOLOGIES CORPORATION – PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two Class I directors—Robert Hershberg, PhD | 2026-04-24 |
| Annual report FY2025 ADAPTIVE BIOTECHNOLOGIES CORPORATION – 10-K SUMMARY (2025) HEADLINE NUMBERS • Revenue 2025: $277.0 million (vs. $179.0 million in 2024), up 55% • MR | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Raises full year 2026 MRD revenue guidance to $268-$278 million range Adaptive Biotechnologies reported strong Q2 2026 results with total revenue of $71.6 million, up 22% year-over-year. The company's core MRD (Minimal Residual Disease) business performed exce | 2026-07-29 |
| Raises full year 2026 MRD revenue guidance to $260-$270 million range Adaptive Biotechnologies reported strong Q1 2026 results with total revenue of $70.9 million, up 35% year-over-year. The company's flagship MRD (Minimal Residual Disease) business drove perf | 2026-05-05 |
| Raises full year 2025 MRD revenue guidance to $202-207 million range Adaptive Biotechnologies reported strong Q3 2025 results with major milestones. Total revenue was $94.0 million (102% growth year-over-year), though this includes $33.7 million from amortizi | 2025-11-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adaptive Biotechnologies Corp — free to start.
Google PlayApp StoreData updated 2026-09-18.